Tear Sheet

Company Overview

HTG Molecular Diagnostics, Inc.'s mission is to empower precision medicine at the local level. The company’s proprietary HTG EdgeSeq technology automates multiplexed molecular profiling of nucleic acids in a wide variety of solid and liquid samples, even when very limited in amount. The extraction free workflow paired with detection by next-generation sequencing offers many advantages and enables meaningful applications, such as identifying biomarkers important for precision medicine, understanding the clinical relevance of these biomarkers, and, ultimately, identifying treatment options.

Stock Quote

Copyright West LLC. Minimum 15 minutes delayed.

News Releases

Date Title and Summary
Toggle Summary HTG Molecular Diagnostics Announces the Institute of Oncology Research Has Adopted the HTG EdgeSeq Technology in its Genomics Facility
HTG’s extraction-free, targeted next-generation sequencing technology adopted to support the IOR’s research and clinical trials in hematological cancers and solid tumors TUCSON, Ariz. , Oct. 23, 2018 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (“HTG”), a provider of
Toggle Summary HTG Molecular Announces Extension to Precision Diagnostic Partnership (PDP) Program Three for Companion Diagnostic Submission
TUCSON, Ariz. , Sept. 27, 2018 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (“HTG”), a provider of instruments, reagents, and services for molecular profiling applications, today announced that it has entered into an amendment to the third statement of work (“SOW Three”)
Toggle Summary HTG Molecular to Present a Corporate Overview at the Cantor Fitzgerald Global Healthcare Conference
TUCSON, Ariz. , Sept. 26, 2018 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a provider of instruments, reagents, and services for molecular profiling applications, today announced that TJ Johnson, Chief Executive Officer, will present a corporate overview at the Cantor
Toggle Summary HTG Molecular to Present a Corporate Overview at the H.C. Wainwright 20th Annual Global Investment Conference
TUCSON, Ariz. , Aug. 30, 2018 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a provider of instruments, reagents, and services for molecular profiling applications, today announced that TJ Johnson, Chief Executive Officer, will present a corporate overview at the H.C.
Toggle Summary HTG Introduces the HTG EdgeSeq Mouse miRNA Whole Transcriptome Assay, a Comprehensive Panel for miRNA Expression Analysis for use in Translational Medicine and Preclinical Studies
TUCSON, Ariz. , Aug. 29, 2018 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a provider of instruments, reagents, and services for molecular profiling applications, today announced the pre-launch introduction of the new HTG EdgeSeq Mouse miRNA Whole Transcriptome Assay

Stock Chart

SEC Filings

Filing date Description